Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physicians in Training, Communities in Need-Reimagining GME Policy for the Indian Health Service.

JAMA internal medicine·2025
Same author

Perceptions of Institutional Engagement and Inclusion by Sexual Orientation and Gender Identity.

JAMA network open·2025
Same author

Gender Differences in Patient-Physician Communication in Ophthalmic Practice, Pre- and Post-COVID-19 Period.

American journal of ophthalmology·2025
Same author

Visual Field Progression in the Ocular Hypertension Treatment Study.

American journal of ophthalmology·2024
Same author

Quality of Life and Primary Open-Angle Glaucoma in the Ocular Hypertension Treatment Study.

JAMA ophthalmology·2024
Same author

Adopting More Precise Metrics to Move Everyone Closer to Eye Health.

JAMA ophthalmology·2024

Related Experiment Video

Updated: Jun 16, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Considerations in glaucoma therapy: fixed combinations versus their component medications.

Eve J Higginbotham1

  • 1Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, USA. ejhigginbotham@msm.edu

Clinical Ophthalmology (Auckland, N.Z.)
|February 20, 2010
PubMed
Summary

Fixed medication combinations for lowering intraocular pressure (IOP) improve adherence and reduce preservative exposure. Fixed-combination brimonidine/timolol (FCBT) shows superior efficacy and tolerability compared to other fixed combinations for glaucoma management.

Keywords:
adherencebrimonidinefixed combinationglaucomaintraocular pressure

Related Experiment Videos

Last Updated: Jun 16, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Fixed-combination medications for lowering intraocular pressure (IOP) are increasingly utilized for glaucoma and ocular hypertension.
  • These combinations offer advantages like improved patient adherence, convenience, and reduced preservative exposure.

Purpose of the Study:

  • To review the current role of IOP-lowering fixed combinations in disease management.
  • To summarize studies comparing the efficacy and safety of fixed combinations versus their individual components.

Main Methods:

  • Literature review of studies comparing fixed-combination IOP-lowering medications with their component drugs.
  • Focus on fixed combinations including prostaglandin analogs and timolol.
  • Analysis of available data on fixed-combination dorzolamide/timolol (FCDT) and fixed-combination brimonidine/timolol (FCBT) in the US.

Main Results:

  • Both FCDT and FCBT reduce IOP more effectively than monotherapy.
  • FCBT demonstrates a better safety profile and less ocular allergy than brimonidine monotherapy.
  • FCBT appears at least as effective as FCDT for IOP reduction and is better tolerated.

Conclusions:

  • Fixed-combination medications are valuable tools in managing glaucoma and ocular hypertension.
  • FCBT may offer advantages in efficacy, safety, and tolerability compared to FCDT.
  • Further comparative studies on FCDT and FCBT are warranted.